{"filing":{"accession_number":"0001193125-26-332858","cik":"0001070494","ticker":"ACAD","company_name":"ACADIA PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"acad-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1070494/000119312526332858/acad-20260804.htm"},"events":[{"id":23912,"run_id":21627,"accession_number":"0001193125-26-332858","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a straightforward earnings release disclosing Acadia's financial results for the six months ended June 30, 2026. The press release (Exhibit 99.1) reports Q2 2026 revenues of $308 million (up 16% YoY), net income of $32 million, and updated full-year 2026 guidance to $1.24–$1.30 billion in total revenues. The filing explicitly states this is furnished under Item 2.02 (Results of Operations and Financial Condition), the standard Item for earnings disclosures.","company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24272,"accession_number":"0001193125-26-332858","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a straightforward earnings release disclosing Acadia's financial results for the six months ended June 30, 2026. The press release (Exhibit 99.1) reports Q2 2026 revenues of $308 million (up 16% YoY), net income of $32 million, and updated full-year 2026 guidance to $1.24–$1.30 billion in total revenues. The filing explicitly states this is furnished under Item 2.02 (Results of Operations and Financial Condition), the standard Item for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:30:34.216252+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24272,"accession_number":"0001193125-26-332858","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a straightforward earnings release disclosing Acadia's financial results for the six months ended June 30, 2026. The press release (Exhibit 99.1) reports Q2 2026 revenues of $308 million (up 16% YoY), net income of $32 million, and updated full-year 2026 guidance to $1.24–$1.30 billion in total revenues. The filing explicitly states this is furnished under Item 2.02 (Results of Operations and Financial Condition), the standard Item for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:30:34.216252+00:00","company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","filing_date":"2026-08-04"}]}